tiprankstipranks
Trending News
More News >
InspireMD (NSPR)
NASDAQ:NSPR

InspireMD (NSPR) AI Stock Analysis

Compare
693 Followers

Top Page

NS

InspireMD

(NASDAQ:NSPR)

Rating:50Neutral
Price Target:
$2.50
▲(2.88%Upside)
InspireMD's financial performance is constrained by profitability and cash flow issues, impacting its attractiveness. However, recent regulatory approvals and strategic corporate moves offer future growth prospects. Technical indicators point to a neutral to bearish trend.
Positive Factors
Acquisition Potential
InspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.
Analyst Recommendation
Analyst recommends a Buy rating and a $5 price target.
Business Growth
InspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Market Share
Best-in-class data should result in fast share taking for InspireMD's CGuard.
Product Performance
The 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.
Regulatory Approval
InspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Negative Factors

InspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)

InspireMD Business Overview & Revenue Model

Company DescriptionInspireMD, Inc. (NSPR) is a medical device company focused on the development and commercialization of its proprietary MicroNet™ technology for the treatment of complex vascular and coronary artery diseases. The company's flagship product is the CGuard™ Embolic Prevention System (EPS), which is designed to prevent embolization in carotid artery stenting procedures. InspireMD operates primarily in the cardiovascular sector, offering innovative solutions aimed at improving patient outcomes in the treatment of vascular diseases.
How the Company Makes MoneyInspireMD generates revenue through the sale of its CGuard™ Embolic Prevention System and other related products that utilize its MicroNet™ technology. The company's primary revenue stream comes from the direct sales of these medical devices to hospitals, clinics, and other healthcare providers. InspireMD may also earn income through strategic partnerships and distribution agreements with medical device distributors and healthcare organizations. The success of its revenue model is significantly influenced by the clinical adoption of its products, regulatory approvals, and the expansion of its distribution network in various global markets.

InspireMD Earnings Call Summary

Earnings Call Date:May 09, 2025
(Q1-2025)
|
% Change Since: -6.54%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a mix of positive developments and challenges. While there was growth in CGuard revenue and significant progress in clinical trials and commercial preparations, the company faced increased operating expenses and a higher net loss. The anticipated delay in FDA approval also presents a challenge. However, the potential U.S. market opportunity and strategic progress provide optimism.
Q1-2025 Updates
Positive Updates
CGuard Revenue Growth
CGuard revenue reached $1.53 million, reflecting a 1.2% growth year-over-year with 2,611 stents sold.
U.S. Market Opportunity
Potential revenue of $12 million in the U.S. market for CGuard Prime based on current international sales volumes.
Clinical Pipeline Progress
Strong enrollment in C-GUARDIANS II study and first patients enrolled in Tandem Lesion Early Feasibility Study.
Commercial Launch Preparations
Onboarding of 20 sales and marketing professionals and establishment of a facility in Miami for U.S. operations.
Negative Updates
Increased Operating Expenses
Operating expenses for Q1 2025 increased by $4 million or 52.5% compared to Q1 2024, mainly due to expansion-related costs.
Net Loss Increase
Net loss for Q1 2025 was $11.166 million, up from $7.032 million in Q1 2024.
Decline in Cash and Equivalents
Cash and cash equivalents decreased from $34.637 million as of December 31, 2024, to $26.086 million as of March 31, 2025.
FDA Approval Delays
Anticipated delay in FDA approval for CGuard Prime to Q3 2025 due to site audit and regulatory feedback timing.
Company Guidance
In the first quarter of fiscal year 2025, InspireMD reported CGuard revenue of $1.53 million, marking a 1.2% year-over-year growth with 2,611 units sold, contributing to a total of approximately 64,000 implants sold to date. The company remains optimistic for the FDA approval of CGuard Prime in Q3 2025, which could potentially generate $12 million in U.S. revenue based on current market average selling prices (ASPs). Operating expenses increased by 52.5% to $11.75 million due to U.S. sales force expansion and preparation for the CGuard Prime launch. The net loss for the quarter was $11.17 million, with cash and cash equivalents totaling $26.09 million as of March 31, 2025. InspireMD is also advancing its clinical pipeline with strong progress in the C-GUARDIANS II pivotal study, anticipating first-half 2026 approval, and is preparing for the U.S. launch with a team of approximately 20 sales and marketing professionals.

InspireMD Financial Statement Overview

Summary
InspireMD demonstrates revenue growth but faces significant profitability and cash flow challenges. The strong equity position is overshadowed by ongoing operational losses and negative cash flows, posing potential risks. Strategic improvements in operational efficiency and cost management are essential.
Income Statement
45
Neutral
InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.
Balance Sheet
50
Neutral
The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.
Cash Flow
40
Negative
InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.03M7.01M6.21M5.17M4.50M2.48M
Gross Profit1.51M1.51M1.81M1.12M754.00K83.00K
EBITDA-37.24M-33.22M-20.91M-18.52M-14.55M-10.23M
Net Income-36.14M-32.01M-19.92M-18.49M-14.92M-10.54M
Balance Sheet
Total Assets38.67M46.81M47.64M24.65M39.71M17.78M
Cash, Cash Equivalents and Short-Term Investments26.09M34.64M39.02M17.80M34.04M12.64M
Total Debt1.64M2.34M1.59M1.61M1.20M999.00K
Total Liabilities2.96M10.72M8.14M7.26M6.18M5.61M
Stockholders Equity28.34M36.09M39.50M17.39M33.53M12.16M
Cash Flow
Free Cash Flow-27.16M-23.27M-16.76M-16.02M-13.55M-9.17M
Operating Cash Flow-25.60M-21.87M-16.38M-15.54M-13.21M-9.08M
Investing Cash Flow9.53M12.64M-16.09M8.44M-22.46M-187.00K
Financing Cash Flow18.96M18.45M37.53M-140.00K35.03M16.39M

InspireMD Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.43
Price Trends
50DMA
2.43
Positive
100DMA
2.62
Negative
200DMA
2.66
Negative
Market Momentum
MACD
-0.05
Negative
RSI
54.16
Neutral
STOCH
67.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 2.43 is above the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.43, and below the 200-day MA of 2.66, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 67.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.

InspireMD Risk Analysis

InspireMD disclosed 26 risk factors in its most recent earnings report. InspireMD reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

InspireMD Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$75.48M41.953.46%24.75%-61.29%
59
Neutral
HK$15.37B5.76-7.44%4.08%11.55%-28.15%
52
Neutral
$59.55M-67.86%0.34%6.20%
50
Neutral
$68.01M-113.95%8.49%6.09%
47
Neutral
$59.40M-173.47%0.34%9.38%
46
Neutral
$64.49M-94.65%-5.86%50.76%
44
Neutral
$75.24M-117.76%15.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NSPR
InspireMD
2.43
-0.04
-1.62%
VANI
Vivani Medical
1.26
0.01
0.80%
CTSO
Cytosorbents
1.11
0.12
12.12%
SRTS
Sensus Healthcare
4.59
-0.82
-15.16%
HYPR
Hyperfine
0.79
-0.28
-26.17%
ICCM
Icecure Medical
1.06
0.32
43.24%

InspireMD Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
InspireMD Launches CGuard Prime Stent in U.S. Market
Positive
Jul 9, 2025

On July 9, 2025, InspireMD announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System, following FDA premarket application approval. This launch represents a significant milestone for InspireMD, which has already captured a double-digit market share in over 30 countries. The CGuard Prime is designed to enhance embolic protection and improve patient safety in stroke prevention, featuring a dual-layer design and SmartFit™ technology. The launch is expected to strengthen InspireMD’s position in the U.S. market, supported by a seasoned commercial team and robust operational infrastructure.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
InspireMD Gains FDA Approval for CGuard Stent System
Positive
Jun 24, 2025

On June 23, 2025, InspireMD announced that the FDA granted premarket approval for its CGuard Prime Carotid Stent System in the United States, marking a significant milestone for the company. The approval, supported by the C-GUARDIANS pivotal trial, positions InspireMD to launch the stent system in the U.S. market, potentially impacting the carotid stenting industry by offering a less invasive treatment option for carotid artery disease.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
InspireMD Gains CE Mark Approval for CGuard® Prime
Positive
Jun 13, 2025

On June 13, 2025, InspireMD announced it received CE Mark approval under the European Medical Device Regulation (MDR) for its CGuard® Prime Embolic Prevention System (EPS), a significant milestone for the company. This approval allows for the commercial launch of CGuard® Prime EPS in European markets, enhancing InspireMD’s position in carotid stenting innovation and paving the way for a potential U.S. launch pending FDA approval, thereby expanding its market reach and operational scale.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Executive/Board ChangesShareholder Meetings
InspireMD Holds Annual Stockholders Meeting and Elections
Neutral
Jun 3, 2025

On June 3, 2025, InspireMD, Inc. conducted its annual meeting of stockholders, where 66.84% of the shares were represented, constituting a quorum. During the meeting, stockholders re-elected Michael Berman and Scott R. Ward as Class 2 directors for a three-year term and ratified Kesselman & Kesselman as the independent auditors for the 2025 fiscal year.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
InspireMD Appoints New CFO Amidst Strategic Expansion
Positive
Jun 3, 2025

On June 3, 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025. Lawless, who brings extensive financial leadership experience from the healthcare sector, will replace Craig Shore, who has been with the company for nearly 15 years. This leadership change comes as InspireMD prepares for the U.S. launch of its CGuard Prime system, marking a significant phase in its commercial expansion. In connection with his appointment, Lawless will receive an inducement grant of restricted stock and stock options, which will vest over three years, aligning with Nasdaq Listing Rule 5635(c)(4).

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 09, 2025